ST Segment Elevation Myocardial Infarction
32
1
1
14
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 32 trials
100.0%
+13.5% vs benchmark
31%
10 trials in Phase 3/4
7%
1 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 14 completed trials
Clinical Trials (32)
Doxycycline to Protect Heart Muscle After Heart Attacks
Ischemic Postconditioning in STEMI Patients Treated With Primary PCI
Distal Radial Access for Primary PCI in STEMI Patients to Prevent RAO
Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant
Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI
DANish Study of Optimal Acute Treatment of Patients With ST-elevation Myocardial Infarction
Microvascular Dysfunction in Acute Myocardial Infarction (AMI) and Its Relation to Outcome
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI
MAGnesium-based Bioresorbable Scaffold in ST Segment Elevation Myocardial Infarction
Early Prediction of QFR in STEMI-I
Early Assessment of QFR in STEMI-II
Early Prediction of QFR in STEMI-Pharmaco-invasice
Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients With CSFP
Cardiac Care Solution for Coronary Disease Follow up
iFR-guided Revascularization in STEMI
Biomarkers for Risk Stratification After STEMI
Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI
ST Segment Resolution After Primary Percutaneous Coronary Intervention.
Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)
Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction